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Comparing statistical methods in assessing
the prognostic effect of biomarker variability
on time‑to‑event clinical outcomes
Feng Gao1*, Jingqin Luo1, Jingxia Liu1, Fei Wan1, Guoqiao Wang2, Mae Gordon3 and Chengjie Xiong2

Abstract
Background: In recent years there is increasing interest in modeling the effect of early longitudinal biomarker data
on future time-to-event or other outcomes. Sometimes investigators are also interested in knowing whether the variability of biomarkers is independently predictive of clinical outcomes. This question in most applications is addressed
via a two-stage approach where summary statistics such as variance are calculated in the first stage and then used
in models as covariates to predict clinical outcome in the second stage. The objective of this study is to compare the
relative performance of various methods in estimating the effect of biomarker variability.
Methods: A joint model and 4 different two-stage approaches (naïve, landmark analysis, time-dependent Cox
model, and regression calibration) were illustrated using data from a large multi-center randomized phase III trial, the
Ocular Hypertension Treatment Study (OHTS), regarding the association between the variability of intraocular pressure (IOP) and the development of primary open-angle glaucoma (POAG). The model performance was also evaluated in terms of bias using simulated data from the joint model of longitudinal IOP and time to POAG. The parameters
for simulation were chosen after OHTS data, and the association between longitudinal and survival data was introduced via underlying, unobserved, and error-free parameters including subject-specific variance.
Results: In the OHTS data, joint modeling and two-stage methods reached consistent conclusion that IOP variability showed no significant association with the risk of POAG. In the simulated data with no association between IOP
variability and time-to-POAG, all the two-stage methods (except the naïve approach) provided a reliable estimation.
When a moderate effect of IOP variability on POAG was imposed, all the two-stage methods underestimated the true
association as compared with the joint modeling while the model-based two-stage method (regression calibration)
resulted in the least bias.
Conclusion: Regression calibration and joint modelling are the preferred methods in assessing the effect of biomarker variability. Two-stage methods with sample-based measures should be used with caution unless there exists a
relatively long series of longitudinal measurements and/or strong effect size (NCT00000125).
Keywords: Patient-specific variance, Survival data, Longitudinal data, Joint model, Landmark analysis
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Background
As the field of precision medicine continues to advance,
methodologies that utilize individual patient information
over time are becoming increasingly valuable to provide
more accurate prognosis as early as possible. In many
clinical trials and epidemiologic studies, information is
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gathered on both repeated measures of biomarkers (longitudinal data) and clinical outcomes. There is increasing
interest in modeling the longitudinal data and assessing its association with future outcomes. Various methods have been proposed for this goal. The most popular
ones in medical reports are two-stage methods where
sample-based descriptive statistics such as mean are first
calculated for each individual and subsequently used as
covariates (i.e., assumed known and free of measurement
error) into conventional models such as linear regression or Cox proportional hazard model for a clinical outcome. Several studies have compared different statistical
methods that relate the characteristics derived from early
longitudinal data to future clinical outcomes. For example, Tu et al. [1] examined various approaches (tracing
the z-scores, life-course plots and models, life-course
path analysis, conditional body size analysis, multilevel
analysis, latent growth curve models and growth mixture
models) for the repeated measurements of weights from
early ages to assess its relationship with blood pressure at
age 19. Sayers et al. [2] using simulated data compared 4
different two-stage methods with a joint model in relating childhood growth to adult blood pressure. They concluded that sample-based summary measures tend to
result in biased estimation for the association, while multilevel growth model (model-based two-stage or regression calibration) and joint modeling lead to unbiased
result. Sweeting et al. [3] assessed the predictive ability of
repeated blood pressure for the time-to-cardiovascular
disease outcome. They compared various naive methods
(baseline-only model, last observation carry-over forward, and cumulative mean) against more complex models (regression calibration (RC), risk-set RC, and joint
modeling), but only observed a modest improvement in
terms of discrimination and calibration as compared to
the baseline-only model. Crozier et al. [4] also discussed
recent development in methods to characterize the prenatal and early growth and its impact on whole body
bone mass at age 6, though they focused more on complex model-based approaches.
All the above studies focus on the mean level or trajectory of the longitudinal measurements. In some studies,
however, it is also of interest to know whether the variability (or stability) of a biomarker is predictive of outcomes. In an ophthalmology study based on subjects
with at least 3-year follow-up, for example, Caprioli and
Colman [5] found that long-term IOP fluctuation (measured as standard deviation of each individual’s longitudinal IOP) is associated with visual field progression in
patients with POAG. Segar et al. [6] revealed that the variability in kidney function and serum electrolyte indices
is independently associated with worse clinical outcomes
in patients with chronic stable heart failure. Muntner
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et al. [7] and Whittle et al. [8] assessed data from the
ALLHAT Pragmatic Trial and found that the visit-to-visit
variability of blood pressure is an independent predictor for cardiovascular disease and chronic renal disease
outcomes, respectively. Recently, it was also reported
that cognitive variability predicts the onset of Alzheimer
disease dementia [9]. Despite the recent development of
joint models [10, 11], two-stage approach remains the
mainstream in medical applications for assessing the
effect of within-subject biomarker variability on clinical outcomes. To the best of our knowledge, however, no
papers have yet compared the relative performance of
various methods under this setting.
In this paper, several two-stage methods and a joint
model were illustrated using data from a large multicenter randomized phase III trial, the Ocular Hypertension Treatment Study (OHTS), regarding the association
between the variability of intraocular pressure (IOP)
and the development of primary open-angle glaucoma
(POAG). We also compared the relative performance
of two-stage methods using simulated data where the
association between longitudinal and survival data was
introduced via underlying, unobserved, and error-free
parameters including subject-specific variance [10, 11].
The model parameters for simulation were selected based
on the analysis of OHTS data. This paper is organized as
follows. Section 2 describes the OHTS data, model constructions, and computational implementation. Section 3
presents the results to illustrate various models using
OHTS data and compares their performance by simulations. Finally, Sect. 4 concludes with a discussion.

Methods
Motivating example: Ocular Hypertension Treatment Study
(OHTS)

OHTS is a large multi-center randomized phase III
trial to evaluate the safety and efficacy of topical ocular hypotensive medication in delaying the onset of primary open-angle glaucoma (POAG) which is among the
leading causes of blindness in US and worldwide. 1636
subjects were randomized to either observation or treatment with ocular hypotensive medication and followed
for a median of 78 months. A prediction model to identify ocular hypertensive subjects who are at high risk
for developing POAG has been developed from OHTS
data and been widely used in the ophthalmology community [12]. The prediction model includes 5 baseline
factors—age, intraocular pressure (IOP), central corneal
thickness (CCT), pattern standard deviation (PSD), and
vertical cup to disc ratio (VCDR). Among these factors,
IOP is the only factor that can be modified by current
treatment. As of today, many studies have confirmed
that a decrease in mean IOP level can reduce the risk of
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developing POAG. There is still controversy about the
impact of IOP variability on POAG.
The analysis cohort for the current study consisted of
709 participants who were randomized to the observation arm, had completed at least two post-randomization visits (i.e., with at least 3 IOP measurements), and
had complete baseline data for age, IOP, CCT, PSD, and
VCDR. The eye-specific predictors (IOP, CCT, PSD,
VCDR) were based on the first eye with POAG or a
randomly selected eye in participants without POAG.
The primary endpoint was time from randomization to the POAG onset. Those subjects who did not
develop POAG were censored at the date of study closeout. These baseline predictors were standardized to
have mean 0 and variance 1 and the coefficients from
the regression models represented the effect per 1-SD
change. The objective of current study is to compare
the performance of different statistical methods, and
a detailed interpretation on the effect of IOP variability for the risk of POAG has been described in Gordon
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et al. [13]. An exploratory analysis was performed by
fitting a simple linear regression model of IOPs against
measurement times to each subject to estimate intercept, slope and (logarithm transformed) variance of
residuals. Figure 1 explored the relationship between
these IOP-derived characteristics (which were further
categorized into quartiles) and the risk of developing POAG. There was a dramatically increased risk of
developing POAG in the 4th quartile of IOP intercept
(Fig. 1B). Similar trend was shown in IOP slope though
the relationship may not be linear (Fig. 1C), while a
substantial overlap was noted across quartiles of the
within-subject IOP variability (Fig. 1D).
Models for data analysis and simulation

Data were analyzed by a joint model of longitudinal and
survival data, as well as 4 different two-stage models to
assess the association between longitudinal and survival outcomes, especially for the effect of biomarker
variability.

Fig. 1 An exploratory analysis to assess the association between IOP-derived subject-specific characteristics (i.e., intercept, slope, and variance of
residuals from the OLS model of IOPs against measurement times) and the risk of developing POAG using the OHTS data. A raw data of longitudinal
IOP over follow-up time; B risk of developing POAG by the quartiles of IOP intercept; C risk of developing POAG by the quartiles of IOP slope; D risk
of POAG by the quartiles of within-subject IOP variability
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Notations

Suppose there were N subjects. Let T
 i = min(Di, Ci) be
the observed survival time for the ith subject, where Di
was the potential failure time and Ci was the potential
censoring time independent of Di. Let Δi be the corresponding censoring indicator, with Δi = 1 if Ti = Di and
Δi = 0 otherwise. Let Y
 ij denote the longitudinal data for
ith individual at time tij, and the longitudinal data only
included those measurements taken prior to the time
of event or censoring. Finally, we denoted the baseline
covariates predictive of longitudinal and survival processes as X
 i and Z
 i respectively, which may or may not be
the same.
Joint model assessing biomarker variability on survival
outcome

The joint model consists of two sub-models, a measurement model for longitudinal data and an intensity model
for survival data, and the two sub-models are associated
via shared latent random effects including subject-specific variance [14]. Specifically,
• the measurement sub-model describes the trajectory
of longitudinal data using a linear mixed model,

Yij = β0 + β1 tij + β2 Xi + Ii + Si tij + eij

(1)

eij ∼ N 0, σvi2 and log σvi2 = µV + Ui
⎛ 𝜎I2
⎛ Ii ⎞
⎛⎛0⎞ ⎞
𝜌12 𝜎I 𝜎S 𝜌13 𝜎I 𝜎V ⎞
⎜ ⎟
⎟
⎜
⎜⎜ ⎟ ⎟
𝜎S2
𝜌23 𝜎S 𝜎V ⎟
⎜ Si ⎟ ∼ N ⎜⎜0⎟ , Σ⎟, and Σ = ⎜ 𝜌12 𝜎I 𝜎S
⎜ ⎟
⎟
⎜
⎜⎜ ⎟ ⎟
2
𝜎V ⎠
⎝Ui ⎠
⎝𝜌13 𝜎I 𝜎V 𝜌23 𝜎S 𝜎V
⎝⎝0 ⎠ ⎠

• where β0 and β1 represents intercept and slope,
respectively, and β2 is a vector of parameters for
other baseline covariates. Ii and Si are the subjectspecific random intercept and slope as in a conventional linear mixed model [15]. eij is the error for
subject i at time j, independently following a normal
distribution with a mean zero and variance σvi2 . We
assume a log-linear relationship between the overall
variance, µV , and the subject-specific random variance, Ui . { Ii , S i , Ui } is the vector of random effects
with its distribution defined as i.i.d. multivariate normal with a mean vector {0, 0, 0} and a symmetric and
positive-definite variance–covariance ∑. {σI2 , σS2 , σV2 }
is the vector of variance parameters of Ii , S i , andUi .
{ρ12 , ρ13 , ρ23} is the vector of correlation parameters
among the random effects. That is, unlike the conventional linear mixed models, model (1) explicitly
allowed subject-specific variance. The above model is

similar to our previous joint model [10] except that
its variance–covariance matrix has been extended
following Leckie et al. [16] to allow exploring the full
correlation among all subject-specific random effects.
• the intensity sub-model is a semi-parametric piecewise exponential distribution,

i (t) = 0 (t)exp(α0 + α1 Zi + γ1 Ii + γ2 Si + γ3 Ui )

(2)
• where λ0(t) is the baseline hazard when all covariates are 0. The subject-specific random effects
Ii , Si , and Ui are from model (1) and thus induced
association between the longitudinal and the survival
process, with γ3 specifically for the effect of wthinsubject biomarker variability. α0 denotes intercept
and α1 is a vector of parameters for other baseline
covariates. To obtain a flexible estimate to λ0(t), we
split the survival time into K subintervals (with a
known value for K) and assume λ0(t) being a stepfunction with height k at each interval (tk , tk+1 ), for
k = 1, 2, …, K.
The full joint distribution is specified in the form of,

f (Y, T, θ) = f (Y|θ)f (T|Y, θ)f (θ)
with θ = {β, α, γ, µV ,k , σI2, σS2, σV2 , ρ12, ρ13,ρ23} the
unknown parameters as given in models (1) and (2), and
estimated under a Bayesian framework using Markov
Chain Monte Carlo (MCMC) method [17]. The following prior distributions are specified for the unknown
parameters,

α, β, γ , µv ∼ N(0, 100),

k ∼ G(0.1, 1), and

�




0.01 0
0
∼ IW 0 0.01 0 
0
0 0.01

where N (a, b) denoted a Normal distribution with
mean a and variance b, G(a, b) represented a Gamma
distribution with mean a/b and variance a/b2, and IW
represented an inverse-Wishart distribution which is an
inverse of 3-dimension Gamma distribution. The resultant posterior distributions are a multivariate normal distribution for the measurement sub-model and a Poisson
distribution for the intensity sub-model at the kth interval
(tk , tk+1 ).
Two‑stage models assessing biomarker variability on survival
outcome

In a two-stage analysis, only longitudinal data are analyzed in the first stage to estimate summary statistics
for each individual, and these summary statistics are
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then used as covariates in the regression models in the
second stage. In this study, 4 different two-stage models
are considered.
1. Simple approach (Naïve): In the first stage, a simple
ordinary least square (OLS) regression model is fitted to each subject separately and includes measurements from all available visits to estimate intercept
( Ii ), slope ( Si ), and the variance of residuals (Ui ) for
ith subject. In the second stage, the above estimates
are used as covariates in a Cox proportional hazards
model to assess their prognostic effects on the time
to POAG, where the hazard function for ith subject is
defined as,

i (t) = 0 (t) exp (α1 Zi + γ1 Ii + γ2 Si + γ3 Ui ).
2. Landmark analysis (LMA): A set of visits are first
selected as landmark points. In the first stage, a
series of OLS models are fitted to each individual.
Each OLS model includes longitudinal measurements accumulated up to the given landmark point
to estimate intercept ( Iil ), slope ( Sil ), and the variance of residuals (Uil ) for ith subject at lth landmark
point. In the second stage, these estimates are used
as fixed covariates in a series of conventional Cox
models and each model is fitted at a given landmark
point onwards (i.e., including participants still at risk
of developing an endpoint). The hazard function for
ith subject at lth landmark point is defined as,

il (t) = 0l (t)exp(α1 Zi + γ1 Iil + γ2 Sil + γ3 Uil )
where 0l represents the unspecified baseline hazard function at lth landmark point and {γ1,γ2,γ3}is the
vector of average effects across landmark points. {γ1
,γ2,γ3} is estimated similar to that of Van Houwelingen [18] by stacking the datasets across all landmark
points and using robust sandwich variance for the
precision of estimation. One main difference is that
we fitted a stratified (stratified by landmark points)
Cox model and left the baseline hazard 0l (t) totally
unspecified, while Van Houwelingen [18] adapted a
delayed entry to ensure a uniform time scale across
all models and thus to estimate baseline hazard
function.
3. Cox model with time-dependent covariates (td-Cox):
In the first stage, a series of OLS models are fitted in
a similar way as the above LMA to estimate intercept
( Iil ), slope ( Sil ), and the variance of residuals (Uil ) for
ith subject at lth visit. In the second stage, their effects
on POAG are assessed using a Cox proportional hazards model with time-dependent covariates, and the
hazard function for ith subject is defined as,
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i (t) = 0 (t)exp(α1 Zi + γ1 Ii (t) + γ2 Si (t) + γ3 Ui (t))
where {Ii (t), Si (t), Ui (t)} represents time-varying
covariates incorporated via a counting process style
[19] for { Iil , Sil , Uil } at different visits.
4. Regression Calibration (RC): this approach has been
widely used in the measurement error framework
where model-based (rather than sample-based) estimates are used as covariates in the regression analysis
in the second stage to assess the association between
biomarker-derived characteristics and clinical outcome [2, 3]. Specifically, RC is essentially a two-stage
implementation of the joint model as specified in
Sect. 2.2.1. In the first stage, Model (1) is fitted to all
subjects to estimate the subject-specific intercept ( Ii ),
slope ( Si ), and the variance of residuals (Ui ). In the
second stage, these model-based estimates are used
as covariates into a Cox model, where the hazard
function for ith subject is defined as,

i (t) = 0 (t)exp(α1 Zi + γ1 Ii + γ2 Si + γ3 Ui )
For comparison with the joint model (the true model
used for data simulating later on), logarithm transformed variance of residuals from OLS was actually
used as the measure of within-subject variability
throughout this paper. Note that at least 3 repeated
measurements are needed in order to fit an OLS
model in a given subject. In the analysis of OHTS
data, only those subjects who had at least 3 measurements were included in fitting these models, even
though this restriction was not required for the joint
model and RC for a fair comparison. In the simulation studies, for each subject we set a minimum leadin time (i.e., 1 year) where we started to collect longitudinal measurements prior to the time-0 of survival
model and thus avoided excluding any simulated subjects from analysis.
Computational implementation

The unknown parameters θ = {β, α, γ, µV , k , σI2, σS2, σV2 ,
ρ12, ρ13,ρ23} in the joint model and RC were fitted using
the Gibbs sampling built into the software WinBUGS
(http://www.mrc-bsu.cam.ac.uk/bugs/). The parameter
estimates and standard errors were calculated as the
mean and standard deviation of the posterior samples
from Gibb’s sampling. The estimation procedure was
implemented using the R2WinBUGS library in the statistical package R [20]. We used three parallel MCMC
sampling chains with different starting values. The convergence of each chain was monitored by the trace
plots and the diagnostic statistics of Gelman et al. [17].
Following recommendations by Goldstein et al. [21]
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for hierarchical models with random effect in level-1
variance, we took a relatively long adaptation period
for MCMC. In the analysis of OHTS data, the posterior
mean of the parameters were based on 25,000 iterations following a 25,000-iteration of burn-in period. In
the simulated data, we used 15,000 iterations following
a 15,000-iteration of burn-in period to reduce computational time. All the other two-stage models were fitted
using the survival library in the statistical package R.

Results
Ocular Hypertension Treatment Study (OHTS)

The OHTS analysis cohort included 709 participants
with a median of 14 IOP measurements (range 3–17)
and a median follow–up of 6.9 years (range 1.0–8.1).
A total of 97 participants developed POAG endpoints
during follow-up. The OHTS data were analyzed by
joint model and two-stage methods, adjusting baseline factors (age, CCT, and VCDR) in both longitudinal (IOP) and survival (POAG) sub-models (R codes

for RC and joint model listed in the Supplementary
Materials). In LMA, a total of 9 visits, semi-annually
at time = {1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5}, were selected
as the landmark points. Table 1 showed the estimated
parameters ( θ ) and standard error (SE) from the joint
model and the two-stage methods. Means and standard deviations for the sample-based estimates {Ii, Si,
Ui} from the Naïve, LMA, and tdCox models were also
included in Table 1. Because each subject had series
of estimates across different landmark points (visits)
in LMA and tdCox, the estimates at 3-year (i.e., the
median landmark point) were presented for illustration.
As expected, the estimates from the sample-based twostage models showed relatively large SDs especially in
the IOP slope and within-subject IOP variability.
• In the longitudinal sub-model of joint model, we
observed significant between-subject variation in
the random intercepts, slopes, as well as the withinsubject fluctuation. There was a weak but significant

Table 1 Estimated parameters (θ ) and its standard error (SE) for the association between the longitudinal intraocular pressure (IOP)
and the risk of developing primary open-angle glaucoma (POAG) based on the OHTS data
Parameters

Joint Model

RC

LMAa

Naive

θ

SE

θ

SE

θ

  Intercept (β0 )

24.55*

0.108

24.57*

0.109

24.60

24.65

  Slope (β1 )

-0.169*

0.021

-0.179*

0.021

-0.037

-0.180

-0.180

  Age (decades)(β 2 )

0.244*

0.106

0.235*

0.112

–

–

–

  CCT (β 3 )

0.045

0.108

0.031

0.103

–

–

–

  VCD (β 4 )

-0.063

0.110

-0.071

0.110

–

–

–

Longitudinal model:

SE

tdCoxa

θ

SE

θ

SE

Fixed effects
24.65

Random effects
   SD of Intercept (σI )

2.514*

0.088

2.518*

0.088

3.098

3.031

3.031

   SD of slope (σS )

0.412*

0.021

0.410*

0.021

1.393

1.664

1.664

   SD of variation (σV )

0.668*

0.027

0.668*

0.027

0.905

1.012

1.012

   Mean of variation (µV )

1.641*

0.031

1.639*

0.030

2.185

1.090

1.090

  Correlation (ρ12 )

0.131*

0.060

0.113*

0.059

–

–

–

  Correlation (ρ13 )

0.183*

0.051

0.181*

0.050

–

–

–

  Correlation (ρ23 )

0.235*

0.059

0.228*

0.060

–

–

–

Survival model:
Baseline factor
  

Age (decades)(α 1 )

0.216

0.125

0.182

0.110

0.082

0.107

0.114

0.109

0.102

   CCT (α 2 )

-0.639*

0.129

-0.644*

0.113

-0.672*

0.110

-0.643*

0.129

-0.662*

0.107
0.112

   VCD (α 3 )

0.543*

0.142

0.526*

0.116

0.549*

0.111

0.425*

0.112

0.517*

0.112

  Intercept (γ1 )

0.226*

0.056

0.275*

0.047

0.212*

0.034

0.161*

0.038

0.203*

0.034

  Slope (γ2 )

1.190*

0.514

0.852*

0.348

0.038

0.054

0.017

0.048

0.026

0.051

   Variation (γ3 )

0.121

0.228

0.103

0.183

-0.052

0.094

0.108

0.084

0.071

0.084

Effects of follow-up IOP

*

P < 0.05; RC Regression calibration; Naïve: simple OLS; LMA Landmark analysis, td-Cox: time-dependent Cox model

a

Based on the subject-specific intercept, slope, and logarithm transformed variance of residuals estimated at the 3-year landmark point
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decrease of IOP over time (with slope β1 = −0.17
mmHg/year), and the change varied considerably
between participants, i.e., with a standard deviation
of random slope σS = 0.41 as comparing to its average trajectory (β1 = −0.17). The random intercept
and within-subject variation also varied significantly
across participants, but the magnitude of standard deviations (σI = 2.51 for random intercept and
σV = 0.67 for within-subject variability) were not so
big as comparing to the corresponding mean levels
(β0 = 24.55andµV = 1.64). The analysis revealed
only weak correlation between intercept and slope
(ρ12 = 0.13), intercept and variation (ρ13 = 0.18), as
well as between slope and variation (ρ23 = 0.24).
• The survival sub-model of joint model showed
baseline hazards function of λ0(t) = {0.001 ± 0.001,
0.003 ± 0.002,
0.006 ± 0.002,
0.014 ± 0.004,
0.017 ± 0.005, 0.011 ± 0.004, 0.043 ± 0.015} at time
intervals t = {0, 2, 3, 4, 5, 6, 7, ∞}, respectively. The
model indicated that those subjects with high mean
IOP or large slope had a significantly increased risk
to develop POAG (γ1 = 0.23, 95% credit interval (CI):
0.12, 0.34; γ2 = 1.19, 95% CI: 0.23, 2.24), and there
was no significant association between IOP variability and POAG (γ3=0.12, 95% CI: -0.32, 0.57).
• Among these two-stage methods, RC reached exactly
the same conclusion as the joint model, while all
other 3 methods showed that only IOP intercept
was significantly associated with POAG. One reason for the inconsistent results is that sample-based
two-stage models are more sensitive to the number
of data points in the longitudinal IOPs when calculating subject-specific estimates, especially for slope
(Si) and variability (Ui). For a subject with very short
IOP series, for example, one may end up with low S
i
(and/or Ui) because a short IOP series does not allow
enough room for fluctuation. On the other hand, one
may end up with high Si (and/or Ui) because a short
IOP series is more sensitive to potential outliers.
Consequently, this could result in non-linear relationship (as shown in Fig. 1) and decreased statistical
power. In contrast, a model-based two-stage methods such as RC allows borrowing information from
similar subjects and leads to more reliable subjectspecific estimates. An exploratory analysis similar to
that of Fig. 1 was performed using subject-specific
estimates from RC and the assumption of linearity
was well satisfied in all estimates (Supplementary
Fig. 1). An exploratory analysis was also performed
regarding the precision of estimation and it revealed
that a relatively long series of IOPs is needed in order
to reliably estimate the within-subject variability
(Supplementary Materials).
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• Two sensitivity analyses were further performed
using the OHTS data. The first sensitivity analysis
compared a joint model with an exponential survival
sub-model to the one with a piecewise exponential survival. The estimated parameters were listed
side by side for an easy comparison and very small
differences were found (Supplementary Table 1). In
the second sensitivity analysis, the two-stage models
were defined using both Bayesian and non-Bayesian paradigm, and the estimated parameters were
very close under both framework (Supplementary
Table 2). Therefore, to reduce computational time in
the subsequent simulation study, the data were generated from a joint model with exponential survival
and all the sample-based two-stage models were analyzed using standard software under non-Bayesian
framework.

Simulation study

Two sets of simulations were conducted to assess the
relative performance of the two-stage methods. The first
simulation was designed to assess the impact of the number of longitudinal measurements on detecting the association between within-subject variability and survival
outcome. The second simulation assessed the influence
of random effects on estimation. Data were generated
from the joint model with an exponential survival distribution, and censoring times were introduced from
a uniform distribution U [1, 8] that was independent of
survival time. Model parameters θ = {β, α, γ, µV , σI2, σS2,
ρ12, ρ13, ρ23} were modified after the OHTS joint model.
The model performance was summarized as the bias of
the estimated parameters relative to the true values. Each
simulated scenario included 100 samples (mainly due to
intensive computation in the joint model and the regression calibration model) and each sample included 500
subjects with approximately 80% censoring rate.
Impact of frequency and number of longitudinal
measurements

The data were simulated under a total of 16 scenarios
based on the combinations of 4 conditions (see Table 2):
the frequency of measurements (semi-annually vs. quarterly), the minimum lead-in times (1-year vs. 3-year), the
average IOP change over time (β1 = 0 vs. β1 = -0.5), and
the strength of association between within-subject IOP
variability and POAG (γ3 = 0 vs. γ3 = 0.5). Specifically,
• The number of longitudinal measurements were
determined by the frequency of visits and lead-in
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Table 2 Average of estimated effect of biomarker variability (γ3) on survival outcome and its standard error (SE) from the joint model
and two-stage methods based on the first simulation
Simulated scenarios

naive

Frequency of visits

Min #visits
β1
(lead-in time)

Semi-annually

3 (1-yr)

0.0
-0.5

7 (3-yr)

0.0
-0.5

Quarterly

5 (1-yr)

0.0
-0.5

13 (3-yr)

0.0
-0.5

γ3

Scenario#

γ3

LMA
SE

γ3

td-Cox
SE

γ3

RC
SE

γ3

Joint model
SE

γ3

SE

0.0

1

-0.353

0.053

0.002

0.034

0.001

0.042

0.039

0.129

0.011

0.150

0.5

2

-0.238

0.060

0.067

0.038

0.076

0.046

0.372

0.128

0.507

0.154

0.0

3

-0.355

0.054

0.002

0.035

0.003

0.042

0.018

0.127

-0.017

0.149

0.5

4

-0.226

0.060

0.074

0.039

0.088

0.045

0.419

0.126

0.528

0.161

0.0

5

-0.129

0.081

-0.019

0.081

-0.018

0.075

0.044

0.117

0.002

0.129

0.5

6

0.197

0.084

0.243

0.085

0.259

0.078

0.483

0.115

0.499

0.132

0.0

7

-0.121

0.081

-0.014

0.080

-0.005

0.075

0.003

0.117

-0.010

0.127

0.5

8

0.191

0.084

0.243

0.083

0.258

0.077

0.452

0.121

0.521

0.136

0.0

9

-0.214

0.083

-0.006

0.068

-0.012

0.069

0.002

0.114

-0.015

0.124

0.5

10

0.122

0.086

0.218

0.073

0.232

0.072

0.452

0.115

0.489

0.129

0.0

11

-0.222

0.084

0.004

0.068

-0.013

0.069

0.017

0.112

0.011

0.124

0.5

12

0.102

0.086

0.205

0.073

0.222

0.072

0.413

0.113

0.524

0.131

0.0

13

-0.080

0.090

-0.014

0.097

-0.025

0.087

0.008

0.107

0.005

0.113

0.5

14

0.299

0.092

0.313

0.098

0.321

0.088

0.474

0.109

0.515

0.115

0.0

15

-0.074

0.091

-0.024

0.096

-0.023

0.087

0.001

0.108

-0.005

0.111

0.5

16

0.302

0.091

0.314

0.098

0.321

0.088

0.462

0.108

0.519

0.119

RC Regression calibration; Naïve: simple OLS; LMA Landmark analysis, td-Cox Time-dependent Cox model

time. For a trial with semi-annual frequency, for
example, the longitudinal data were generated at
times t = {-1, -0.5, 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0,
4.5, 5.0} given 1-year lead-in time and at times t = {-3,
-2.5, -2, -1.5, -1, -0.5, 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5,
4.0, 4.5, 5.0} given 3-year lead-in time. For simplicity,
in the simulation we assume all subjects with equalspaced measurements, but this is not necessary in
general as a linear regression has been used to estimate subject-specific summary statistics.
• A baseline covariate (X) was generated from a standard normal distribution N(0,1), and the covariate was
assumed to have effect on both survival time (α1 = 0.5)
and longitudinal data (β2 = 1.0). All other parameters
remained constant across all simulated scenarios, with
β0 = 25, γ1 = 0.2, γ2 = 1.0, σI=2.5, σS=0.4,µV =1.5, σV
=0.7, ρ12=0.1, ρ13=0.2, and ρ23=0.2.
The simulated data were analyzed by the joint model
and two-stage methods. The visits at time = {0, 1, 2, 3,
4, 5} were selected as landmark points in LMA and also
used as the time intervals to calculate time-dependent
covariates in td-Cox. The average estimated effect of biomarker variability (γ3) and its standard error (SE) were
presented in Table 2 and summarized below. All other
estimated parameters were presented in the Supplementary Table 4.

• Naïve showed the worst performance among all
comparison models, especially under scenarios with
short lead-in time or low measurement frequency.
Given 1-year lead-in time, for example, it showed a
significant negative association (γ3 < 0) when there
was actually no association (γ3 = 0), and it led to
severe underestimation when there existed a moderate association (γ3 = 0.5).
• LMA had a better performance as comparing to
Naïve. It resulted in a reliable estimation when there
was no association (γ3 = 0). When there existed an
association (γ3 = 0.5), however, LMA also suffered
from severe underestimation under scenarios with
short lead-in time and/or low measurement frequency.
• td-Cox had almost identical performance as LMA
under all simulated scenarios. This was consistent to
what was reported in Putter and Van Houwelingen
[22]. They studied the relationship between regression coefficients obtained in time-dependent Cox
model and landmark analysis, and found that the two
models are well agreed when there is no rapid change
over time in the time-varying effects.
• RC had the best performance among all two-stage
methods. This observation was consistent to the
findings in Sayers et al. [2] that model-based twostage methods have a much better performance than
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sample-based ones. The results also showed that a
relatively long series of longitudinal biomarkers are
needed when the effect of within-subject biomarker
variability is of interest. For example, at least 7 measurements were needed in order to produce an estimation with less than 10% bias using RC.

Impact of the random effects from longitudinal data

Data in the second simulation were generated using the
same models as the first simulation, except that the interest is to explore model performance under different magnitude of underlying variance–covariance components.
Specifically,
• Data were simulated under the following 4 scenarios
with a non-factorial design, assuming all the correlation coefficients ρ12= ρ13= ρ23=0. Values in the
parentheses were selected based on OHTS model
and held constant when data were simulated under
other scenarios.
(1) σI (SD of random intercept): 0.5, 1.5, (2.5), 3.5,
5.0;
(2) σS(SD of random slope): 0.1, 0.2, (0.4), 0.7, 1.0;
(3) σV (SD of within-subject variability): 0.4, (0.7),
1.0, 1.5, 2.5;
(4) µV (Mean of within-subject variability): 0.5, 1.0,
(1.5), 2.0, 3.0.
• In all the simulated scenarios, we assumed a moderate assocation between IOP variability and POAG
(γ3 = 0.5). The frequency of visits was set semiannually with a 2-year lead-in period. All the other
parameters remained constant across all scenarios,
with β0 = 25, β1 = -0.2, β2 = 1.0, α0 = 0.5, γ1 = 0.2, and
γ2 = 1.0.
Figure 2A-D showed the average estimated effect of
biomarker variability (γ3) under the above 4 scenarios,
respectively. The average estimates of other parameters
were also presented in Supplementary Tables 5, 6, 7 and
8, respectively.
• In Scenario 1 (Fig. 2A), Naive showed the largest bias
and RC performed the best among the two-stage
methods. LMA and td-Cox, having almost identical performance, fell in-between. The results also
showed that, at least within the range of specified
values, σI had little impact on estimating γ3. Similar
observations were made in the Scenario 4 (Fig. 2D)
for the varying µV .
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• In Scenario 2 (Fig. 2B), the relative performance of
two-stage methods remained the same as above, but
the performance of all the methods slightly decreased
as σS increased.
• In Scenario 3 (Fig. 2C), the accuracy of estimation for
all two-stage methods improved as σV increased and
Naïve converged to LMA and td-Cox in the presence of a strong within-subject variability. When
there existed very weak within-subject variability, all
methods had a poor performance to detect the effect
of variability on outcome—the joint model produced
slightly overestimation and all two-stage methods
resulted in severe underestimation.

Discussion
In this paper, using simulated data we compared the relative performance of several two-stage methods in estimating the prognostic effect of biomarker variability on
survival outcome. These two-stage methods were chosen for evaluation because they have been widely used
in medical applications or thoroughly evaluated in other
studies against joint models [2, 3]. Among these methods,
the simple approach (Naïve) provides an easy interpretation, requires the least efforts in data manipulation and
model fit, and thus gains most popularity in practical use.
However, our simulations revealed that it had the worst
performance among all the compared methods. Under
the scenarios with relatively short longitudinal measurements, for example, the naïve approach resulted in negative association when there is actually no association and
suffered from severe underestimation when there exists
a moderate association. One reason is that the naïve
model fails to control the number of data points in a longitudinal predictor when calculating the subject-specific
estimates. Since those subjects with higher risk are more
likely to develop event earlier, the number of data points
is also associated with clinical outcome. LMA and td-Cox
showed improved performance. They provided reliable
estimation when there exists no association, but both
still suffered from substantial downward bias in the presence of moderate association. Consistent to the previous
researches [1–3], the model-based two-stage method
(i.e., RC) produced the least bias among all the two-stage
methods. In addition, the results showed that, at least
within the range of evaluated scenarios, a relatively long
series of measurements (i.e., minimum 7 readings) are
needed in order to produce an estimation with < 10% bias
for the effect of biomarker variability.
In the analysis of longitudinal data (and multi-level
data in general), it has been a long tradition to focus
on mean level and/or trajectory, while treating withinsubject variability (or level-1 variance) as nuisance
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Fig. 2 Average estimated effect of biomarker variability on survival outcome (γ3) from the joint model and two-stage methods based on
the second simulation, where the dotted red-line represents the true value (γ3 = 0.5). A γ3 as function of varying SD of random intercept; B
γ3 as function of varying SD of random slope; C γ3 as function of varying SD of within-subject variability; D γ3 as function of varying mean of
within-subject variability

parameters. The presence of excessive heterogeneity for
within-subject variability often serves as a sign of model
misspecification, providing evidence of missing important predictor(s) for the mean function of the model [23].
In recent years, however, there is an increasing interest
in modeling heterogeneity of level-1 variance. Rast et al.
[24] and Goldstein et al. [21] among other relaxed the
assumption of homogenous variance in multi-level mixed
models, not only modelling the level-1 variance as a loglinear function of subjects’ characteristics but also allowing the association among random effects in the mean
and level-1 variance. Leckie et al. [16] summarized the
recent development in this field and also reviewed the
software options for fitting such extensions. Martins [11]

proposed a joint model with flexible links using standard
deviation of residuals as a predictor to assess the stability
of CD4 counts on survival outcome in patients with HIV/
AIDS. Such a joint model allows simultaneously accounting for the measurement errors in both longitudinal and
survival processes, uses information more efficiently and
leads to unbiased estimates regarding the “true” relationship between longitudinal and survival data.
Despite the recent progress in joint models [10, 11],
two-stage methods remain the most popular approach
in assessing the prognostic effect of within-subject biomarker variability on clinical outcomes [5–8]. Several factors contribute to the popularity of two-stage
approaches. First, these methods can produce tangible
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descriptive statistics for each individual regarding biomarker variability/trajectory and thus facilitate an easy
interpretation. Second, the wealth of theory and software
that have been developed for the conventional regression
analyses have greatly smoothed the process of model fitting and diagnosis. In addition, graphical techniques such
as Kaplan–Meier curves are readily available under a
two-stage analysis framework. However, all the two-stage
methods share the potential problem that the uncertainty in the estimates from the first stage is not taken
into account when assessing their association with clinical outcome, and it is well known that failure to account
for the error in covariates can bias parameter estimates
downward to null values [25]. Our simulations suggested
that these sample-based two-stage methods (i.e., Naïve,
LMA, and td-Cox) be used with caution to assess the
effect of within-subject variability on future outcomes,
unless a relatively long series of longitudinal biomarkers
is available for each subject and/or there exists a strong
effect size.
Several alternative approaches are available for introducing the association between variability and clinical
outcomes. For example, Henderson et al. [26] introduced
a within-subject autocorrelation to the longitudinal submodel to account for “wiggles” over time and they added
a frailty into survival sub-model to accommodate any
effect that cannot be explained by the shared random
intercept and slope. Jiang et al. [27] took a growth mixture model approach and the association between biomarker variability and clinical outcome was introduced
via distinct sub-groups (latent classes) as determined by
unique longitudinal patterns. In this study, we selected a
joint model that directly relates the within-subject variability of longitudinal data as a predictor to the survival
outcome [10, 11]. This model possesses some attractive
features on modeling the within-subject variability and
is relatively straightforward to interpret as comparing
to the frailty-model or growth mixture framework. For
example, the effect of variability on clinical outcome can
be readily quantified as hazard ratio (e.g.,HR = exp(γ3 ))
and makes it easy to model the effect under the standard
framework such as Cox proportional hazards model.
Many potential variants of the aforementioned twostage methods are also available for assessing the effect
of biomarker variability, depending on which summary
statistics are used and how the statistics are estimated.
For example, one possible method is the “risk-set RC” in
Sweeting et al. [3]. It is essentially a mixture of LMA and
ordinary RC, where a regression calibration is performed
at each landmark point. Per reviewer’s comments to distinguish between two-stage methods with and without
future information (i.e., using longitudinal measurements
only prior to certain time T to estimate the summary
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statistics at time T), we also explored the potential performance of Naïve and RC without future information via
simulated data. As an illustration, the longitudinal data in
both methods only included measurements taken during
lead-in periods. Therefore, the new methods under consideration were essentially a special case of the LMA and
risk-set RC, respectively (i.e., LMA or risk-set RC with a
single landmark point at time 0). The results showed that
the new Naïve has similar performance as LMA, while
the performance of new RC is comparable to that of the
ordinary RC (Supplementary Table 3).
In this study, although the simulation studies were performed based on OHTS data, we expect that the observation is generalizable to similar researches in general. One
potential limitation of our study is the intensive computational time for joint modelling and RC approach. In the
analysis of OHTS data (N = 709), for example, the joint
model and RC took approximately 40 min when using 3
parallel chains with 50,000 iterations each. In contrast,
those sample-based two-stage approaches with standard
software took almost no computation time. To make a
simulation study feasible, we used a moderate sample size
(N = 500) with 30,000 iterations, but it still took about
10 min for each replicate. Each simulation therefore only
included 100 replicates.

Conclusion
A relatively long series of longitudinal measurements is
required when the effect of biomarker variability is of interest. Model-based two-stage method (regression calibration) and joint modelling are the preferred methods to fulfil
this goal. In contrast, sample-based two-stage methods
should be used with caution unless there exists a long series
of longitudinal measurements and/or strong effect size.
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